CORRECTION article

Front. Neurol., 14 February 2022

Sec. Neuroepidemiology

Volume 13 - 2022 | https://doi.org/10.3389/fneur.2022.857959

Corrigendum: A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy

  • 1. Department of Neurology, Xiangya Hospital, Central South University, Changsha, China

  • 2. Institute of Molecular Precision Medicine and Hunan Key Laboratory of Molecular Precision Medicine, Xiangya Hospital, Central South University, Changsha, China

In the original article, there was an error. In the Abstract there was a mistake in the statement of the results of the pooled prevalence of congenital myopathy in the all-age population. Instead of ā€œThe pooled prevalence of congenital myopathy in the all-age population was 1.50 (95% CI, 0.93–2.06) per 100,000, while the prevalence in the child population was 2.73 (95% CI, 1.34–4.12) per 100,000ā€, it should be ā€œThe pooled prevalence of congenital myopathy in the all-age population was 1.62 (95% CI, 1.13–2.11) per 100,000, while the prevalence in the child population was 2.76 (95% CI, 1.34–4.18) per 100,000.ā€

A correction has been made to Abstract, Results, Paragraph 1:

Results: A total of 11 studies were included in the systematic review and meta-analysis. Of the 11 studies included, 10 (90.9%) were considered medium-quality, one (9.1%) was considered low-quality, and no study was assessed as having a high overall quality. The pooled prevalence of congenital myopathy in the all-age population was 1.62 (95% CI, 1.13–2.11) per 100,000, while the prevalence in the child population was 2.76 (95% CI, 1.34–4.18) per 100,000. In the pediatric population, the prevalence among males was 2.92 (95% CI, āˆ’1.70 to 7.55) per 100,000, while the prevalence among females was 2.47 (95% CI, āˆ’1.67 to 6.61) per 100,000. The prevalence estimates of the all-age population per 100,000 were 0.20 (95% CI 0.10–0.35) for nemaline myopathy, 0.37 (95% CI 0.21–0.53) for core myopathy, 0.08 (95% CI āˆ’0.01 to 0.18) for centronuclear myopathy, 0.23 (95% CI 0.04–0.42) for congenital fiber-type disproportion myopathy, and 0.34 (95% CI, 0.24–0.44) for unspecified congenital myopathies. In addition, the prevalence estimates of the pediatric population per 100,000 were 0.22 (95% CI 0.03–0.40) for nemaline myopathy, 0.46 (95% CI 0.03–0.90) for core myopathy, 0.44 (95% CI 0.03–0.84) for centronuclear myopathy, 0.25 (95% CI āˆ’0.05 to 0.54) for congenital fiber-type disproportion myopathy, and 2.63 (95% CI 1.64–3.62) for unspecified congenital myopathies.

In the original article, there was a mistake in Table 1 as published. The number of cases in the reference Norwood et al. should be 41, not 18. The corrected Table 1 appears below.

Table 1

ReferencesCountry/regionAge (years)Data sourceDiagnostic criteriaPrevalence datePopulation sizeNumber of casesPrevalence per 100,000 (95% CI)Overall scored
Amburgey et al. (21)United States (Michigan)<18Hospital/clinic chart review, administrative databaseClinical history with at least 1 additional supporting study (biopsy, genetic testing, or first-degree relative)20101,211,100463.80 (2.93, 4.66)Medium
Chung et al. (22)Southern China (Hong Kong)<19Hospital/clinic chart review, administrative databaseEuropean Neuromuscular Center (23), World Federation of Neurology Research Committee (24)a2001.06.301,335,469453.22 (2.43, 4.01)Medium
Darin and Tulinius (25)Western Sweden<16Mailed survey, hospital/clinic chart review, administrative databasesMuscle and Nerve (26)b1995.01.01359,676185.01 (3.37, 6.64)Medium
Hughes et al. (27)Northern IrelandAllHospital/clinic chart review, administrative database, relatives.European Neuromuscular Center (23), World Federation of Neurology Research Committee (24)a1994.06.301,573,282573.62 (2.87, 4.37)Medium
Lefter et al. (28)Ireland>18Hospital/clinic chart review, administrative databaseTable e-1 at Neurology.org (28)2013.12.313,439,565330.96 (0.65, 1.27)Medium
Norwood et al. (29)Northern EnglandAllHospital/clinic chart review, administrative databaseEuropean Neuromuscular Center (23), Monogenic neuromuscular disorders (30)c2007.08.012,990,000410.60 (0.33, 0.87)Medium
Pagola-Lorz et al. (31)Northern Spain (Navarre)AllHospital/clinic chart review, administrative databaseMonogenic neuromuscular disorders (32), undiagnosed genetic muscle disease (33)c2016640,64781.25 (0.44, 2.06)Medium
Santos et al. (34)Portugal<15NMDetails are not available20011,656,602271.63 (1.07, 2.19)Low
Tangsrud and Halvorsen (35)Southern Norway<18Mailed survey, hospital/clinic chart reviewSystem proposed by Dubowitz (36)b1983.01.01573,76230.52 (āˆ’0.05, 1.10)Medium
Theadom et al. (37)New ZealandAllHospital/clinic chart review, administrative databaseDetails are not available2014.04.014,242,048601.41 (1.08, 1.75)Medium
Witting et al. (38)Denmark>5Mailed survey, hospital/clinic chart review, administrative databaseHighly dependent on histological findingsNM5,400,000821.52 (1.22, 1.82)Medium

Characteristics of the included studies on congenital myopathy prevalence.

CI, confidence interval; NM, not mentioned.

a

Diagnosis based on characteristic histochemical abnormalities.

b

Highly dependent on histological findings.

c

Genetic confirmation or clinical phenotype + characteristic histological findings.

d

Quality of study reporting assessment; details are shown in Supplementary Material 2.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 21.

    AmburgeyKMcnamaraNBennettLRMccormickMEAcsadiGDowlingJJ. Prevalence of congenital myopathies in a representative pediatric united states population. Ann Neurol. (2011) 70:662–5. 10.1002/ana.22510

  • 22.

    ChungBWongVIpP. Prevalence of neuromuscular diseases in Chinese children: a study in southern China. J Child Neurol. (2003) 18:217–9. 10.1177/08830738030180030201

  • 23.

    DubowitzV. Diagnostic criteria for neuromuscular disorders: Edited by Alan E. H. Emery. Published 1994, European Neuromuscular Centre, Baarn, The Netherlands. ISBN 90 261 0719 6, 72 pp. Neuromuscular Disord. (1994) 4:292–3. 10.1016/0960-8966(94)90038-8

  • 24.

    World Federation of Neurology Research Committee Research Group on Neuromuscular Diseases. J Neurol Sci. (1988) 86, 333–360.

  • 25.

    DarinNTuliniusM. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord. (2000) 10:1–9. 10.1016/S0960-8966(99)00055-3

  • 26.

    BrookeMHCarrollJERingelSP. Congenital hypotonia revisited. Muscle Nerve. (1979) 2:84–100. 10.1002/mus.880020203

  • 27.

    HughesMIHicksEMNevinNCPattersonVH. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord. (1996) 6:69–73. 10.1016/0960-8966(94)00017-4

  • 28.

    LefterSHardimanORyanAM. A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. Neurology. (2017) 88:304–13. 10.1212/WNL.0000000000003504

  • 29.

    NorwoodFLHarlingCChinneryPFEagleMBushbyKStraubV. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. (2009) 132:3175–86. 10.1093/brain/awp236

  • 30.

    KaplanJC. Gene table of monogenic neuromuscular disorders (nuclear genome only) Vol 19. No 1 January 2009. Neuromuscul Disord. (2009) 19:77–98. 10.1016/j.nmd.2008.11.001

  • 31.

    Pagola-LorzIVicenteEIbanezBTorneLElizalde-BeirasIGarcia-SolaesaVet al. Epidemiological study and genetic characterization of inherited muscle diseases in a northern Spanish region. Orphanet J Rare Dis. (2019) 14:276. 10.1186/s13023-019-1227-x

  • 32.

    BonneGRivierFHamrounD. The 2018 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord. (2017) 27:1152–83. 10.1016/j.nmd.2017.10.005

  • 33.

    HarrisELavalSHudsonJBarresiRDe WaeleLStraubVet al. Undiagnosed genetic muscle disease in the north of England: an in depth phenotype analysis. PLoS Curr. (2013) 5:ecurrents.md.37f840ca67f5e722945ecf755f40487e. 10.1371/currents.md.37f840ca67f5e722945ecf755f40487e

  • 34.

    SantosMAFinezaIMorenoTCabralPFerreiraJCSilvaRLet al. G.P.7 07 Epidemiology of neuromuscular disorders in Portugal at pediatric age. Neuromuscular Disord. (2006) 16:703. 10.1016/j.nmd.2006.05.192

  • 35.

    TangsrudSEHalvorsenS. Child neuromuscular disease in southern Norway. Prevalence, age and distribution of diagnosis with special reference to ā€œnon-Duchenne muscular dystrophyā€. Clin Genet. (1988) 34:145–52. 10.1111/j.1399-0004.1988.tb02854.x

  • 36.

    DubowitzV. Muscle disorders in childhood. Major Probl Clin Pediatr. (1978) 16:iii–xiii, 1–282.

  • 37.

    TheadomARodriguesMPokeGO'gradyGLoveDHammond-TookeGet al. A Nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology. (2019) 52:128–35. 10.1159/000494115

  • 38.

    WittingNWerlauffUDunoMVissingJ. Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark. Neurol Genet. (2017) 3:e140. 10.1212/NXG.0000000000000140

Summary

Keywords

prevalence, congenital myopathy, nemaline myopathy, core myopathy, centronuclear myopathy, congenital fiber-type disproportion myopathy

Citation

Huang K, Bi F-F and Yang H (2022) Corrigendum: A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy. Front. Neurol. 13:857959. doi: 10.3389/fneur.2022.857959

Received

19 January 2022

Accepted

19 January 2022

Published

14 February 2022

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

13 - 2022

Updates

Copyright

*Correspondence: Fang-Fang Bi Huan Yang

This article was submitted to Neuroepidemiology, a section of the journal Frontiers in Neurology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics